20 YEARS OF PROFESSIONAL & DEDICATED SERVICE TO GLOBAL CUSTOMERS

Custom Manufacturing, Project Outsourcing, your Trusted Partner from China

Sourcing LY2157299: A Chemist's Guide to a Key Cancer Research Compound

For research chemists and pharmaceutical scientists, the ability to source high-quality, well-characterized chemical compounds is fundamental to the success of their work. When delving into complex biological pathways like the TGF-β signaling network and its role in diseases such as cancer, access to specific inhibitors is non-negotiable. This is where compounds like LY2157299, also identified by its CAS number 700874-72-2, become indispensable.

LY2157299, widely recognized as Galunisertib, is a potent and selective TGF-β receptor 1 (TGF-βRI) kinase inhibitor. Its significance in cancer research stems from its ability to modulate pathways that are often dysregulated in malignant cells, influencing processes such as cell proliferation, invasion, and immune suppression. This makes it a valuable tool for exploring new therapeutic strategies and understanding disease mechanisms.

When it comes to purchasing such specialized compounds, a chemist’s priority is purity, consistency, and a reliable supply chain. For researchers worldwide, sourcing from established manufacturers in China offers distinct advantages, particularly for advanced pharmaceutical intermediates. We understand the critical nature of these requirements and are dedicated to providing LY2157299 that meets rigorous quality standards.

Our role as a manufacturer and supplier in China means we can offer competitive pricing and ensure a stable supply for your ongoing research and development projects. Whether you require small quantities for initial screening or larger batches for pre-clinical studies, our team is equipped to handle your needs. We focus on delivering not just a product, but also the assurance that your experiments will yield accurate and reproducible results.

For scientists looking to buy LY2157299, engaging with a direct manufacturer simplifies the procurement process and can lead to better cost efficiencies. We encourage you to reach out to us for detailed product specifications, pricing, and to discuss your specific research requirements. Partnering with a dependable supplier is the first step towards accelerating your discovery in the critical field of cancer therapeutics.

Manufacturing Facilities

NINGBO INNO PHARMCHEM CO.,LTD. was established in 2007. It is committed to the R&D, production and sales of raw materials, pharmaceutical intermediates and fine chemicals. We striving to create a high-efficiency and high-quality integrated chemical service platform to better serve domestic and foreign customers.

Professional Export Experience

to Global Customers

WHY CHOSE US?

1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;

2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;

3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).

FAQ

  • A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.

  • A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.

  • A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.

CONTACT US
Should you need to contact us; you may call during regular business hours, Monday through Friday, 8am – 6 pm.
NINGBO INNO PHARMCHEM CO.,LTD.
Address: No.163 Ruiqing Rd.,Ningbo 315000 China
Phone: 86-574-87319282
Fax: 86-574-27912196
SEND US AN EMAIL

NAME*

EMAIL*

COMPANY

COUNTRY*

MESSAGE*

Previous: Unlocking Cancer Therapies: The Role of TGF-β Receptor Inhibitors

Next: Galunisertib: A TGF-β Inhibitor Driving Innovation in Cancer Immunotherapy

All Rights Reserved